Implementation of a Multiprofessional Competence and Consultation Center for Optimizing Medication Safety in Oral Antitumor Therapy: Patient Surveys and Analysis of Drug-related Problems

Not Applicable

• Conditions: all tumor entities treated with an oral antitumor drug; C00-D48; Neoplasms

• Registration Number: DRKS00026272
• Lead Sponsor: Apotheke des Universitätsklinikums Erlangen; Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie der FAU Erlangen-Nürnberg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-10-04
• Results First Posted: 2023-06-03
• Study Completion: 2024-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 551

Inclusion Criteria

existing therapy with an oral anticancer agent or initiation of therapy with an oral anticancer agent, treatment at the CCC Erlangen-EMN or cooperating practices, ability to complete questionnaires

Exclusion Criteria

lack of german language skills (in written or spoken form), cognitive impairment, non-consenting patients, missing written consent

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
At least 70 % of patients treated with oral antitumor drugs at the CCC Erlangen-EMN are counselled by the Competence and Consultation Center for Medication Safety. (descriptive)

Secondary Outcome Measures

Name	Time	Method
e.g. rates and severity of side effects (questionnaire), health-related quality of life (questionnaire), patient knowledge (questionnaire), medication errors (descriptive) number of referring institutions and physicians (descriptive)